
Female power United in Prevention! Listen to the great ideas the presidents of the ESC Associations have shared in an amazing session at #ESCPrev2025 #escprevmotions @EAPCPresident @denisamuraru @PTBuketAkinci @AnastasiaSMihai

Cardiologist passionate about research

Female power United in Prevention! Listen to the great ideas the presidents of the ESC Associations have shared in an amazing session at #ESCPrev2025 #escprevmotions @EAPCPresident @denisamuraru @PTBuketAkinci @AnastasiaSMihai

Join us for the next EAPC Journal Club on Friday, 20 November 2026, for an engaging discussion on the clinical implications of baseline anaemia and short dual antiplatelet therapy in patients at high bleeding risk undergoing PCI. Featuring expert insights from Prof. Sebastiano Sciaretta (Senior Commentator), Dr Luigi Spadafora (Speaker), and Dr Francesca Maria di Muro and Dr Gal Tsaban (Discussants). Moderated by Dr Svetlana Moșteoru. 📷 Friday, 20 November 2026 📷 17:00–18:00 CET Don't miss this opportunity to explore the evidence, challenge clinical perspectives and discuss what it means for everyday cardiovascular practice. Event open for everyone! Register now! esc365.escardio.org/event/28… @EAPCPresident

✅Lp(a) at the #AHA congress: no 💊 pharma yet on the HORIZON. So should we still screen it ? Does Knowing Lp(a) Change What We Do? See the debate in #EJPC ⤵️ academic.oup.com/eurjpc/arti…

Acute exposure to 🚬 promotes vascular dysfunction, ⬆️ venous CO2, and acute 🧬 damages in healthy 🧑🦱👩🦱 adults. Explore more insights in the recent #EJPC paper ⤵️ 🔗doi.org/10.1093/eurjpc/zwag5…

In patients with coronary heart disease, 150 min/wk of moderate-intensity physical activity was associated with 38% lower all-cause mortality. A dose–response meta-analysis of 176,862 patients highlights the benefits of low-to-moderate activity levels. 🔗 doi.org/10.1093/eurjpc/zwag5…

Drug-Coated Balloons vs Drug-Eluting Stents: What Does the Evidence Show? Our new meta-analysis of 10 RCTs (7,832 patients) led by @CorballisTash @TheLancet @eClinicalMed No difference in cardiovascular death or MI. But revasc may be higher. thelancet.com/journals/eclin… @NNUH

📉 Fewer ischemic events, but more bleeding after heart attack? SWEDEHEART data showed declining CV events but increasing bleeding complications, particularly upper GIS bleeding. Tailored antithrombotic therapy and gastroprotection remain essential. 🔗 doi.org/10.1093/eurjpc/zwag5…

🫀Fear of cardiac symptoms may become a barrier to recovery. A systematic review of 26 studies (n=9,628) found heart-focused anxiety in 15–49% of patients with CVD, linked to exercise avoidance and poorer outcomes. 🔗 doi.org/10.1093/eurjpc/zwag5…

🤰🫀 Hyperlipidaemia in pregnancy: physiology or cardiovascular risk? A timely review of peripartum lipid changes, maternal & fetal outcomes, treatment options, and key evidence gaps. 🔗 doi.org/10.1093/eurjpc/zwaf3…

Younger age at first diagnosis is strongly associated with lower risk of subsequent events in patients with cerebrovascular disease (stroke) and in women with peripheral artery disease or abdominal aortic aneurysm 📖 doi.org/10.1093/eurjpc/zwag0… @escardio @AboyansV @SilCastelletti

In this population-based cohort, standard modifiable CV risk factors status significantly impacted long-term but not short-term mortality following MI 📖 doi.org/10.1093/eurjpc/zwaf2… @escardio @AboyansV @SilCastelletti @PeroneFrancesco @PTBuketAkinci @SMosteoru @TimKambic

This systematic review and meta-analysis suggests that LDL-C-lowering therapies may offer a greater benefit in preventing first-time MI compared with recurrent MI 📖 doi.org/10.1093/eurjpc/zwaf3… @escardio @AboyansV @SilCastelletti @PeroneFrancesco @PTBuketAkinci @SMosteoru @TimKambic

Our second event in this year’s EAS Advanced Courses on non-classical risk factors series will take place in Prague, Czech Republic. The application process is now open. Join us to learn about the potential role of non-classical factors including chronic inflammation, metabolic disturbances, gut microbiota, psychosocial stress, and environmental influences in cardiovascular disease risk and progression. Register here: eas.to/NCRFCZReg

Our EAS Advanced Courses on non-classical risk factors are back! While traditional risk factors such as high blood pressure, elevated cholesterol, smoking, and diabetes are well recognised, emerging evidence highlights the potential role of non-classical factors - including chronic inflammation, metabolic disturbances, gut microbiota, psychosocial stress, and environmental influences - in cardiovascular disease risk and progression. Join us in Athens, Greece, for the first event in the 2026 series, and register now: eas.to/NCRFGRReg

An interesting session on the final morning of #ESCCongress 2026 🫀 Residual risk beyond LDL-C: achieving LDL-C targets is only part of the story. Lp(a), persistent inflammation and cardiometabolic risk may help identify the patients who remain at risk — and increasingly provide targets for intervention. Great perspectives on Lp(a), colchicine and GLP-1 therapies presented by great faculty. @escardio @TokgozogluLale @KoKoMaung_ @GalTsaban @SMosteoru #preventivecardiology

A landmark moment for preventive cardiology during the #ESCCongress 2026: the first-ever ESC Guidelines dedicated to Cardiac Rehabilitation. A comprehensive, multidisciplinary and patient-centred rehabilitation takes centre stage — with individualized exercise, risk-factor management, shared decision-making and new approaches to delivery. @escardio @KoKoMaung_ @GalTsaban @SMosteoru #preventivecardiology